title: [Drug selection and treatment goal in osteoporosis therapy.]
abstract: The goal of treatment for osteoporosis is to reduce the risk of fracture. Achieving effective reductions in the risk of fracture requires evidence-based drug selection and careful consideration of patient background, including concomitant diseases and drug adherence. Selective estrogen receptor modulators(SERM)and active vitamin D3such as eldecalcitol are well indicated in early menopausal women with no history of fragility fractures. Moreover, elderly individuals with a history of fragility fractures are at high risk of vertebral and hip fractures, so bisphosphonates, denosumab and teriparatide are well indicated in these patients. Although no well-established goal has been devised for the treatment of osteoporosis in Japan, the strategy of goal-directed treatment of osteoporosis has been reported in the United States.
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
authors.forename: Mika
authors.initials: M
authors.lastname: Yamauchi
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D020845:Selective Estrogen Receptor Modulators